Agios Pharmaceuticals Inc (NASDAQ: AGIO) is 37.54% higher on its value in year-to-date trading and has touched a low of $19.80 and a high of $35.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AGIO stock was last observed hovering at around $29.94 in the last trading session, with the day’s gains setting it 0.69%.
Currently trading at $30.63, the stock is 4.71% and 7.14% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.8 million and changing 2.30% at the moment leaves the stock 20.57% off its SMA200. AGIO registered 39.61% gain for a year compared to 6-month gain of 28.86%. The firm has a 50-day simple moving average (SMA 50) of $37.89 and a 200-day simple moving average (SMA200) of -$2.64.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 1.12% loss in the last 1 month and extending the period to 3 months gives it a 30.90%, and is 9.71% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.55% over the week and 3.67% over the month.
Agios Pharmaceuticals Inc (AGIO) has around 383 employees, a market worth around $1.72B and $26.82M in sales. Profit margin for the company is -1312.63%. Distance from 52-week low is 54.74% and -13.72% from its 52-week high. The company has generated returns on investments over the last 12 months (-40.56%).
Agios Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$1.64 with sales reaching $8.69M over the same period.The EPS is expected to shrink by -5.34% this year, but quarterly earnings will post 59.00% year-over-year. Quarterly sales are estimated to grow 54.90% in year-over-year returns.
267 institutions hold shares in Agios Pharmaceuticals Inc (AGIO), with institutional investors hold 109.52% of the company’s shares. The shares outstanding are 55.95M, and float is at 54.74M with Short Float at 12.06%. Institutions hold 107.75% of the Float.
The top institutional shareholder in the company is Wellington Management Group, LLP with over 5.87 million shares valued at $166.11 million. The investor’s holdings represent 10.52% of the AGIO Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 5.52 million shares valued at $156.31 million to account for 9.90% of the shares outstanding. The other top investors are Blackrock Inc. which holds 4.73 million shares representing 8.48% and valued at over $133.85 million, while Bellevue Group AG holds 7.20% of the shares totaling 4.01 million with a market value of $113.66 million.
Agios Pharmaceuticals Inc (AGIO) Insider Activity
The most recent transaction is an insider sale by FOUSE JACQUALYN A, the company’s Director. SEC filings show that FOUSE JACQUALYN A sold 7,791 shares of the company’s common stock on Apr 10 ’24 at a price of $27.55 per share for a total of $0.21 million. Following the sale, the insider now owns 0.14 million shares.
Agios Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 07 ’24 that Foster-Cheek Kaye I (Director) sold a total of 1,285 shares of the company’s common stock. The trade occurred on Mar 07 ’24 and was made at $31.62 per share for $40632.0. Following the transaction, the insider now directly holds 5524.0 shares of the AGIO stock.
Still, SEC filings show that on Mar 06 ’24, Foster-Cheek Kaye I (Director) disposed off 4,415 shares at an average price of $31.99 for $0.14 million. The insider now directly holds 6,809 shares of Agios Pharmaceuticals Inc (AGIO).
